CytoGenix, Inc. (Pink Sheets:CYGX) today announced that it has initiated the process of testing CytoGenix’s novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.
“I fully expect the same if not better results in this new round of testing than that of our mouse tests, expecting that the end result will be a significant benefit to the shareholders of CytoGenix.”
CytoGenix previously reported positive results of an animal study where mice were immunized with CYDBA507, the CytoGenix avian influenza vaccine candidate, which protected against lethal challenge with avian influenza virus. CYDBA507 is built on CytoGenix’s synDNA platform and expresses influenza virus type A/H5N1 HA and NA proteins. The ability of CYDBA507 to express HA and NA proteins in human cells was confirmed in laboratory studies. The CYDBA507 was shown to be as high as 95% effective in some tests.
The emergence of highly pathogenic avian influenza virus type A/H5N1 in domestic poultry and the increasing number of human cases indicates a significant threat to public health because of the potential for pandemic spread of this virus. CytoGenix is developing CYDBA507 for both human use and commercial poultry farming. The development of CYDBA507 as a low cost and more effective vaccine process than other vaccine providers, makes CytoGenix’s product the preferred vaccine.
Lex Cowsert, PhD, CEO of CYGX stated, “Based on successful results of our prior testing, we fully expect that the results of our ferret test will clearly demonstrate the superior quality and effectiveness of the CytoGenix product line. The expected results of our testing will further demonstrate the unprecedented breakthrough technology in the field of DNA vaccines, with the expanding demand for effective bird flu and other vaccines, we feel confident that these results will convert to significant revenue for CytoGenix.”
Cy Stein, MD, PhD, Chairman of the Board of Directors of CYGX stated, “I fully expect the same if not better results in this new round of testing than that of our mouse tests, expecting that the end result will be a significant benefit to the shareholders of CytoGenix.”
Source : CytoGenix, Inc.